Hester Biosciences informs about outcome of board meeting

09 May 2025 Evaluate
Hester Biosciences has informed that Board of Directors, in their Meeting held today, have approved the followings: Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2025, as recommended by Audit Committee and the Audited Standalone and Consolidated Financial Statements for the year ended 31 March 2025. Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended time to time), we hereby state that the Statutory Auditors of the Company, Chandulal M. Shah & Co., Chartered Accountants (FRN: 101698W) have issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31 March 2025; Recommended dividend of ?7 (Seven) per equity share of ?10 each (70%) for the financial year 2024-25, subject to approval of members at the ensuing Annual General Meeting; Appointment of Shah & Shah Associates, Company Secretaries, Ahmedabad, as a Secretarial Auditors for a period of five consecutive years from FY 2025-26 to FY 2029-30, as recommended by Audit Committee, subject to approval of members at the ensuing annual general meeting.

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences Share Price

1649.00 17.95 (1.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×